Bioresorbable coronary stents are tube-shaped devices manufactured using biodegradable materials. These stents are used in coronary heart diseases (CAD) surgeries, however, are intended majorly for young adults. Placement of these devices can aid individuals to live with a normal-functioning artery along with the choice to undergo an angioplasty in later years. At present, Magmaris, Absorb BVS, Magnitude, Absorb 2nd Generation, MeRes-100, and DESolve are the leading brands in the field of bioresorbable coronary stents. Most of these pioneers focus on R&D for the development of more advanced and highly efficient products.
Novel Product Development to Fuel Bioresorbable Coronary Stents Demand
Major brands in the filed emphasize on product pipeline development as part of business strategies. In 2016, the Absorb BVS accounted for 97% of the total revenue share. However, the Absorb 2nd generation is likely to witness the maximum demand over the forecast period (from 2016 to 2025). The clinical pipeline of 2nd generation bioresorbable stents with improved device qualities and design features is anticipated to boost the sales across the globe; particularly in the Europe, India, and North America regions.
Furthermore, the MeRes-100 and DESolve brands are also projected to exhibit considerable growth as they provide better results. Magnitude is also expected to have significant results in the clinical follow-up studies as its metallic bioresorbable device, Magmaris, with an underlying metallic body uses a better radial force than other precedents. Most of these brands focus on product innovations in order to gain competitive edge. For instance, on 24, January 2018, REVA Medical, Inc. announced the first implant of the Fantom bioresorbable scaffold (“BRS”) in Italy. Fantom is the new-generation BRS technology consist of Tyrocore polymer, thin struts, and visibility under x-ray angiography.
Market Overview
According to a report by Grand View Research, Inc., the global bioresorbable market is likely to reach USD 247 million by 2025. Growing number of lifestyle diseases and accompanying risk of atherosclerosis-related cardiac events are expected to be the key growth drivers for the market. Rising cases of percutaneous coronary intervention (PCI) procedures along with demand for minimally invasive procedures are also likely to help boost the market growth.
Several other factors such as increasing efforts of companies to conduct clinical trials of bioresorbable stents and increasing use of these stents by surgeons are also expected to have a positive impact on the market growth. Some of the leading companies operating in the market include Meril Lifesciences Pvt. Ltd., Arterial Remodeling Technologies, Elixir Medical Corporation, Biotronik, and Abbott.
Read more at:
Read more at:
1 comment:
This is really an important blog with many helpful information. I have been searching for a long time for this types of content. Keep up posting more and thanks for your great staff.
Used Tadano Cranes Pakistan
Post a Comment